
Last week, the European Crohn's and Colitis Organisation held its 13th annual congress in Vienna, Austria. At the meeting, researchers presented new data on using biosimilar anti–tumor necrosis factor therapies in treating Crohn disease and ulcerative colitis, 2 manifestations of inflammatory bowel disease. Here are 5 things to know about the research presented.

























